SEB Asset Management AB Acquires New Position in Insulet Corporation $PODD

SEB Asset Management AB acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the 1st quarter, HoldingsChannel reports. The firm acquired 117,711 shares of the medical instruments supplier’s stock, valued at approximately $24,700,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Glenmede Investment Management LP boosted its holdings in shares of Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 35 shares in the last quarter. Curi Capital LLC raised its holdings in shares of Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after buying an additional 36 shares in the last quarter. Great Lakes Advisors LLC lifted its position in shares of Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after buying an additional 40 shares during the last quarter. Camarda Financial Advisors LLC lifted its position in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after buying an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet provided an update on its ongoing EVOLUTION T1D clinical study, which is testing a next step in automated insulin delivery and could support the long-term growth story for its Omnipod platform. Article link
• Neutral Sentiment: Several firms issued deadline reminders and investor alerts related to the already-filed securities class action, keeping the lawsuit in focus but not adding new allegations. Article link
• Neutral Sentiment: Additional law-firm notices reiterated the August 31 lead-plaintiff deadline, underscoring ongoing legal risk but mainly serving as promotional updates rather than fresh company developments. Article link
• Negative Sentiment: Multiple securities-fraud class action notices highlighted alleged investor harm tied to Insulet’s manufacturing quality and prior device corrections, which is likely weighing on sentiment and shares. Article link

Analysts Set New Price Targets

A number of research firms have issued reports on PODD. UBS Group set a $219.00 target price on Insulet in a research report on Thursday, June 11th. Raymond James Financial set a $216.00 target price on shares of Insulet in a report on Monday, June 8th. Royal Bank Of Canada reduced their price target on shares of Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Truist Financial decreased their price target on shares of Insulet from $219.00 to $210.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Finally, Wall Street Zen cut shares of Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $235.25.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Insulet Price Performance

Insulet stock opened at $164.06 on Monday. The stock has a 50-day moving average price of $153.00 and a two-hundred day moving average price of $206.34. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88. The company has a market capitalization of $11.36 billion, a PE ratio of 38.15, a P/E/G ratio of 1.15 and a beta of 1.11. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the previous year, the business posted $1.02 earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts expect that Insulet Corporation will post 6.45 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.